Switch theme
Sign up to access all valuation multiples
Acrobiosystems Co Ltd is a global brand focusing on protein technology, products and services in the development of biological drugs. It is committed to providing target antigens and other key reagents and related services required in the development of targeted therapeutic drugs.
2010
n/a
LTM Revenue n/a
LTM EBITDA n/a
$475M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ACROBiosystems has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, ACROBiosystems achieved revenue of $74.9M and an EBITDA of $28.3M.
ACROBiosystems expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ACROBiosystems valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $74.9M | n/a | XXX | XXX | XXX |
| Gross Profit | $49.1M | $60.5M | XXX | XXX | XXX |
| Gross Margin | 66% | NaN% | XXX | XXX | XXX |
| EBITDA | $28.3M | n/a | XXX | XXX | XXX |
| EBITDA Margin | 38% | NaN% | XXX | XXX | XXX |
| Net Profit | $24.0M | $28.1M | XXX | XXX | XXX |
| Net Margin | 32% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, ACROBiosystems's stock price is CNY 43 (or $6).
ACROBiosystems has current market cap of CNY 5.2B (or $718M), and EV of CNY 3.5B (or $475M).
See ACROBiosystems trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $475M | $718M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, ACROBiosystems has market cap of $718M and EV of $475M.
ACROBiosystems's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate ACROBiosystems's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for ACROBiosystems and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $475M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpACROBiosystems's NTM/LTM revenue growth is n/a
ACROBiosystems's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, ACROBiosystems's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate ACROBiosystems's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for ACROBiosystems and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 14% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 23% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 67% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ACROBiosystems acquired XXX companies to date.
Last acquisition by ACROBiosystems was XXXXXXXX, XXXXX XXXXX XXXXXX . ACROBiosystems acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was ACROBiosystems founded? | ACROBiosystems was founded in 2010. |
| Where is ACROBiosystems headquartered? | ACROBiosystems is headquartered in China. |
| Is ACROBiosystems publicy listed? | Yes, ACROBiosystems is a public company listed on SHE. |
| What is the stock symbol of ACROBiosystems? | ACROBiosystems trades under 301080 ticker. |
| When did ACROBiosystems go public? | ACROBiosystems went public in 2021. |
| Who are competitors of ACROBiosystems? | Similar companies to ACROBiosystems include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of ACROBiosystems? | ACROBiosystems's current market cap is $718M |
| Is ACROBiosystems profitable? | Yes, ACROBiosystems is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
